MRX (MRX) Stock Price & Analysis
MRX (MRX) rose 4.31% to USD 60.49 as of June 10, 2026 at 07:19 UTC, according to Nexqual real-time market data.
MRX last closed at USD 57.99; the session ranged USD 58.05–60.85 on volume of 1,422,249 shares. Market capitalization is $4.35B, with a 52-week range of USD 27.91–60.85 (NMS). Source: Nexqual, June 10, 2026 at 07:19 UTC.
Key Statistics (as of June 10, 2026 at 07:19 UTC)
| Price | USD 60.49 |
|---|---|
| Change | ▲ 4.31% (up) |
| Previous Close | USD 57.99 |
| Open | USD 58.68 |
| Day Range | USD 58.05 – 60.85 |
| 52-Week Range | USD 27.91 – 60.85 |
| Volume | 1,422,249 shares |
| Market Cap | $4.35B |
| Exchange | NMS |
Technical Analysis (MRX)
Nexqual's technical model rates MRX "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 07:19 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.6 (neutral) |
| vs SMA50 | Above (USD 52) |
| MACD | 0.84 (positive) |
Analyst Ratings (MRX)
Wall Street analysts rate MRX "Buy" based on 8 analysts, with a mean price target of USD 58.13 (range USD 36–75), per Nexqual as of June 10, 2026 at 07:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 58.13 |
| High Target | USD 75 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (MRX)
| Next Earnings Date | 2026-05-06 |
|---|---|
| EPS Estimate | USD 1.25 |
| Revenue Estimate | $595.88M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.48 vs est 1.38 ▲ beat |
| 2025-12-31 | USD 1.13 vs est 1.02 ▲ beat |
| 2025-09-30 | USD 0.96 vs est 0.94 ▲ beat |
| 2025-06-30 | USD 1.02 vs est 0.93 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Financials & Fundamentals (MRX)
| Total Revenue | $3.27B |
|---|---|
| Revenue Growth (YoY) | +55.10% |
| Gross Margin | +68.86% |
| Operating Margin | +13.08% |
| Profit Margin | +10.63% |
| ROE | +29.06% |
| Debt / Equity | 974.13 |
| Current Ratio | 1.05 |
| Total Cash | $12.02B |
| Total Debt | $13.12B |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Financial Health Score (MRX)
Nexqual rates MRX's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 07:19 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 69%, operating 13% |
| Balance Sheet | Critical — $12.0B cash vs $13.1B debt |
| Cash Flow | Mixed — No data |
| Efficiency | Strong — ROE 29%, ROA 1.1% |
Ownership (MRX)
| Insider Ownership | +15.48% |
|---|---|
| Institutional Ownership | +74.94% |
| Shares Outstanding | 71.93M |
| Float | 51.03M |
| Short % of Float | +4.55% |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Leadership (MRX)
MRX is led by Ian Theo Lowitt (age 61), Group CEO & Executive Director, per Nexqual as of June 10, 2026 at 07:19 UTC.
| Group CEO & Executive Director | Ian Theo Lowitt (age 61) |
|---|---|
| CFO & Director | Crispin Robert John Irvin (age 47) |
| President | Simon James Van Den Born (age 58) |
| Chief Technology Officer | Michael Dugan |
Major Backers & Investors (MRX)
Notable institutional backers of MRX include Capital International Investors, SmallCap World Fund Inc, FMR, LLC, according to Nexqual as of June 10, 2026 at 07:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital International Investors | 4.78% |
| SmallCap World Fund Inc | 4.78% |
| FMR, LLC | 4.77% |
| LOOMIS SAYLES & CO L P | 2.63% |
| Price (T.Rowe) Associates Inc | 2.61% |
| Alliancebernstein L.P. | 2.37% |
| Samlyn Capital, LLC | 2.32% |
| Two Sigma Investments, LP | 2.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.8% |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KG | Kestrel Group, Ltd. | USD 11.78 | ▼ 1.26% |
| TECH | Bio-Techne Corp | USD 54.41 | ▲ 4.65% |
| ALKS | Alkermes plc | USD 44.29 | ▲ 3.48% |
| NBIX | Neurocrine Biosciences, Inc. | USD 165.24 | ▲ 0.83% |
| CRL | Charles River Laboratories Inte | USD 189.85 | ▲ 4.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:19 UTC. This page is informational and not investment advice.